Archive for January 7th, 2009

NJBIZ - J&J Must Supply More Schizophrenia Drug Data to U.S.

Wednesday, January 7th, 2009

NEW BRUNSWICK - Johnson & Johnson must supply more data to United States regulators before they can approve a once-monthly schizophrenia treatment to make up for declining sales of the company’s top -selling drug Risperdal.
The request from the Food and Drug Administration didn’t include a demand for additional studies, New Brunswick-based J&J said in a statement last week. The drug, paliperidone palmitate, is one of two monthly medici…